Headway made towards biosignatures for incipient tuberculosis
- PMID: 31958399
- PMCID: PMC8908387
- DOI: 10.1016/S2213-2600(19)30355-8
Headway made towards biosignatures for incipient tuberculosis
Conflict of interest statement
TJS is co-inventor of patents pending on the Zak16 and Suliman4 signatures that were assessed in the paper by Gupta and colleagues. SCM declares no competing interests.
Comment on
-
Concise whole blood transcriptional signatures for incipient tuberculosis: a systematic review and patient-level pooled meta-analysis.Lancet Respir Med. 2020 Apr;8(4):395-406. doi: 10.1016/S2213-2600(19)30282-6. Epub 2020 Jan 17. Lancet Respir Med. 2020. PMID: 31958400 Free PMC article.
References
-
- WHO. The End TB Strategy: global strategy and targets for tuberculosis prevention, care and control after 2015. World Health Organization, 2015. https://www.who.int/tb/strategy/End_TB_Strategy.pdf?ua=1 (accessed Sept 6, 2019).
-
- Diel R, Loddenkemper R, Nienhaus A. Predictive value of interferon-gamma release assays and tuberculin skin testing for progression from latent TB infection to disease state: a meta-analysis. Chest 2012; 142: 63–75. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical